DAPTEV:深度应用器进化建模用于COVID-19药物设计
Cameron Andress1, Kalli Kappel2, Marcus Elbert Villena3
1Department of Computer Science, Brock University, St. Catharines, Canada.
PLoS computational biology
|July 5, 2023
概括
这项研究介绍了DAPTEV,这是一种创建阿普坦酶序列的智能方法,克服了用于药物发现的传统指数式丰富 (SELEX) 连接体系统演化 (SELEX) 的局限性.
科学领域:
- 生物技术和制药科学 生物技术和制药科学
- 计算生物学 计算生物学
- 分子生物学分子生物学
背景情况:
- 传统的药物发现是昂贵的,缓慢的,容易产生偏见.
- 亚胺为分子标提供高亲和力和特异性,但它们的开发具有挑战性.
- 通过指数式丰富对联体的系统进化 (SELEX) 是一种传统的,但效率低下的,体开发过程.
研究的目的:
- 开发一种智能计算方法,用于aptamer序列生成和进化.
- 为了解决传统的aptamer开发的成本,时间和优化限制.
- 支持和加速基于aptamer的药物发现和开发.
主要方法:
- 开发一种名为DAPTEV的新型智能方法.
- 使用计算方法来生成和演变的阿普坦序列.
- 测试使用COVID-19尖端蛋白作为目标分子的方法.
主要成果:
- DAPTEV证明了产生结构复杂的体的能力.
- 生成的阿普坦体对目标具有强烈的结合亲和力.
- 计算结果显示,与传统方法相比,有了显著的改进.
结论:
- DAPTEV提供了一个有前途的智能解决方案,用于体发现.
- 这种方法可能会降低基于aptamer的药物开发成本和时间.
- 该方法在产生高亲和度的受体对特定标,如COVID-19尖端蛋白的有效性.
相关概念视频
Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).


